Comparative Pharmacology
Head-to-head clinical analysis: CYRAMZA versus VECTIBIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYRAMZA versus VECTIBIX.
CYRAMZA vs VECTIBIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ramucirumab is a human IgG1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.
Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.
8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.
6 mg/kg IV every 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 11–17 days) at steady state, supporting a dosing interval of every 2 weeks.
Terminal half-life approximately 7.5 days (range 3.6–10.9 days); supports every-2-week dosing regimen.
Ramucirumab is eliminated primarily via proteolytic catabolism; no renal or biliary excretion occurs. Clearance is 0.014 L/h (0.022 L/h with high VEGF), with a mean terminal half-life of 14 days (range 11–17 days) at steady state.
Primarily eliminated via the reticuloendothelial system; <3% excreted unchanged in urine; no significant renal or biliary elimination.
Category C
Category C
Antineoplastic Monoclonal Antibody
Antineoplastic Monoclonal Antibody